Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurochem has completed its North American phase III clinical trial for Alzhemed for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
Neurochem said that it is on schedule to release the results of the clinical trial in spring this year. Alzhemed is the company's investigational product candidate aimed at arresting or stopping the progression of Alzheimer's disease.
The primary objective of the clinical trial is to investigate the safety, efficacy and disease-modifying potential of Alzhemed for the treatment of mild-to-moderate Alzheimer's patients. The patients were randomized to receive either placebo or one of two different dose levels of Alzhemed for a period of 18 months.
A phase III extension study was initiated in May of 2006. Approximately 90% of the patients who completed the North American phase III clinical trial have continued into the ongoing extension study and received Alzhemed.
Neurochem is also currently advancing a similar European phase III trial for Alzhemed. The enrolment is scheduled to be completed in early 2007.